Summary
Portal hypertension (PP) is the chief consequence of cirrhosis and is responsible for the majority of its complications. In seventy percentage of cases, PP increases at first as a result of an increased intrahepatic resistance to portal flow attributed to structural mechanisms e.g., fibrous tissue, regenerative nodules, and micro thrombi. Yet, at least one third of the increased intrahepatic resistance is attributed to an increased intrahepatic vascular tone, which, results from endothelial dysfunction mostly mediated from reduced nitric oxide (NO) bioavailability. The onset of portal hypertension may not always be associated with specific symptoms, however, the main symptoms and complications of portal hypertension include; gastrointestinal bleeding due to the spontaneous rupture and bleeding from varices, ascites, hepatic encephalopathy and decreased levels of platelets or decreased white blood cell count. It is currently possible to diagnose liver cirrhosis and portal hypertension accurately by non-invasive methods in a reasonable proportion of patients with chronic liver disease. Recent 
Stages of Cirrhosis and Portal Hypertension
In chronic liver disease, fibrosis progresses leading to cirrhosis and continues to worsen as long as the aetiologic factor is present, fig. (1). The two main stages are the compensated and decompensated stages. The latter is characterized by the presence of clinically overt complications such as; ascites, variceal hemorrhage, or HE. The compensated stage is the longest stage, and it is asymptomatic. There are at least two main sub-stages of compensated cirrhosis with different prognostic and predominant pathophysiological mechanisms: patients with mild PH and those with clinically significant portal hypertension (CSPH). Patients in the latter stage are at risk of developing decompensation, particularly those who have GEV. The decompensated stage is much shorter and can rapidly progress to a stage of further decompensation in which hepatorenal syndrome (HRS) and liver failure (encephalopathy, refractory ascites and jaundice) develop leading to a high mortality 5 .
Figure (1) Stages and sub-stages of cirrhosis

Pathogenesis of Portal Hypertension
In cirrhosis, portal pressure (PP) increases initially as a consequence of an increased intrahepatic resistance to portal flow attributed to structural mechanisms (e.g., fibrous tissue, regenerative nodules) and an increased intrahepatic vascular tone (functional component related to endothelial dysfunction). One of the initial consequences of PH is the formation of portosystemic collaterals. Concomitant or even preceding development of collaterals, splanchnic vasodilatation occurs, leading to increased flow into the gut and into the portal venous system. Vasodilatation leads to activation of neurohumoral and vasoconstrictive systems, sodium and water retention, increased blood volume, and increased cardiac output; that is, a hyperdynamic circulatory state that further increases portal venous inflow and PP. Additionally, norepinephrine, angiotensin-2, and antidiuretic hormone (activated neurohumoral and vasoconstrictive systems) further contribute to intrahepatic vasoconstriction 5,6 . Gastric varices caused by splenic vein thrombosis (SVT) tend to arise from the short gastric veins running from the hilum of the spleen to the greater curvature aspect of the stomach rather than through splenorenal or gastrorenal shunts common with portal hypertensive fundal varices. IVC: inferior vena cava; LGV: left gastric vein; LRV: left renal vein; PV: portal vein; SGV: short gastric vein; SMV: superior mesenteric vein 7 .
Complications of Portal Hypertension Varices
Cirrhotic patients often develop esophageal or gastric varices (GVs) caused by the portosystemic shunting that accompaniesPHT 8 . GVs usually form in the submucosal layer at the cardia or the fundus of the stomach because the posterior wall in this region of the stomach approaches the portosystemic collateral circulation. GVs receive most of their blood supply from the left, posterior, and short gastric veins and drain mainly through a gastrorenal shunt, These GVs and resultant shunts predispose patients to a higher risk of experiencing a massive variceal bleeding 9 . Approximately 35% of patients with compensated cirrhosis and 80% of those with decompensated cirrhosis have varices at the time of diagnosis 9 . Active bleeding at the time of endoscopy is one of the hallmarks for poor prognosis in patients with varices, specially when accompanied by bacterial infection 8 . Mortality rates from variceal bleeding have declined in recent years but still remain high 10 . PHT may also lead to portal hypertensive gastropathy (PHG), a serious condition that can cause acute or even massive blood loss. Endoscopic investigation shows abnormalities in the gastric mucosa often described as a mosaic-like patternthat resembles snake skin. The incidence of PHG, ranging from 2% to 12%, classifies this complication as a less common cause of upper gastrointestinal (GI) bleeding 11 . Rectal varices, frequently confused with hemorrhoids, occur in about 4% of patients with PHT. Since rectal varices seldom bleed, they are of less clinical importance than either esophageal varices or GVs 12 .
Ascites
Ascites develops as a consequence of PHT when fluids accumulate in the peritoneal cavity. It is a major complication of cirrhosis seen in approximately 60% of compensated patients 12 . Arterial splanchnic vasodilatation leads to arterial hypotension with activation of both sympathetic nervous and renin-angiotensin-aldosterone system (RAAS). In cirrhotic patients, as a consequent to the body's failure to excrete sodium into urine sufficiently, excessive sodium accumulation ultimately results in ascites development and edema 13 . Cirrhosis is the main cause of ascites (nearly 75%). The residual 25% of ascites cases are caused by malignancy (10%), cardiac failure (3%), pancreatitis (1%), tuberculosis (2%), or other factors 13 . Pathogenic alterations responsible for ascites in patients with cirrhosis include two separate mechanisms 14 ; increased portal flow resistance at the sinusoids level creating sinusoidal PHT and an associated pressure backwash into the splanchnic capillaries causes the first mechanism. Excess fluid preferentially accumulates in the peritoneal cavity and blood flow increases to the splanchnic area, leading to further increases in portal pressure. The second mechanism precedes ascites formation and relates to sustained renal sodium retention 14 .
Hepatic Hydrothorax
Hepatic hydrothorax (HH) is a term to describe clinically significant pleural effusion greater than 500 mL in cirrhotic patients in absence of cardiac or pulmonary comorbidities 15 . HH usually affects the right side in the majority of cases (87%); less commonly, it occurs in the left side or even bilateral. Of note, even small amounts of pleural effusion can cause significant respiratory embarrassment with negative impact on patient's quality of life 16 .
Hepatorenal Syndrome
Hepatorenal syndrome (HRS) is defined as acute kidney injury in patient with liver failure and cirrhosis as a result of significant reduction in renal perfusion 17 . HRS can be classified into two separate entities (types I and II). Type 2 HRS characterized by slowly progressive renal failure with average serum creatinine of 1.5 mg/dL, type I HRS is found to encompass severe and rapidly progressive renal failure with doubling of the initial serum creatintine levels to above 2.5mg/dl in less than two weeks 17 . Gradual impairment of cardiac functions observed in cirrhotic patients could be another accepted theory 18 . Acute on top of chronic liver failure (ACLF) with multi system affection including impairment of renal function, is a well-known associating feature that goes hand on hand with type 1 H 19 .
Hepatopulmonary Syndrome
Patients with cirrhosis experience at some point certain vascular pulmonary complications including portopulmonary hypertention (PoPH) and hepatopulmonary syndrome (HPS) 20 . PoPH is a condition characterized by elevation of mean pulmonary arterial pressure (mPAP) more than 25 mm Hg at rest or more than 30 mm Hg during exertion; a pulmonary vascular resistance above 240 dynes.s.cm-5; and a capillary wedge pressure below15 mm Hg 21 Hepatopulmonary syndrome (HPS) is a triad of liver disease, pulmonary vascular ectasia and impaired oxygenation. HPS is defined in the literature as a widened alveolar-arterial oxygen difference (Aa gradient) in room air (>15 mm Hg or >20 mm Hg in patients > 64 years of age) with or without hypoxemia due to intrapulmonary vasodilatation in the presence of hepatic dysfunction 22,23 . Clinically, patients with HPS complain of progressive dyspnea on exertion, at rest, or both. Severe hypoxemia (PaO 2 < 60 mm Hg) is often seen and strongly suggests HPS. A classical finding in HPS is orthodeoxia defined as a decreased arterial oxygen tension by more than 4 mm Hg or arterial oxyhemoglobin desaturation by more than 5% with changing position from supine to standing. It is associated with platypnea defined as dyspnea worsened by upright position 22,24 . Orthotopic liver transplantation (OLT) remains the only definitive treatment to HPS with minor role of other strategies such as supplemental oxygen, which gives only symptomatic relief when hypoxemia supervenes can successfully reverse the condition 25 .
Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a neurologic and psychiatric dysfunction in a patient with chronic liver disease. Impaired ability of the liver to detoxify gut-derived neurotoxins is the main cause of this condition 26 . Hepatic encephalopathy (HE) is a serious clinical problem of portal hypertension and cirrhosis. It is manifested by personality changes, cognitive dysfunction, and altered level of consciousness 27,28 . Based on the severity, HE is classified into two groups; Overt HE (OHE) presents episodically or continuously with obvious and clinically detectable symptoms. In contrast, covert HE (CHE) combines the two lowest grades of HE (minimal HE (MHE) and HE grade 1) 29 . Therefore, using the new classification, OHE starts with grade 2 or with evidence of asterixis and disorientation. MHE is characterized by subtle cognitive and psychomotor deficits in the absence of recognizable clinical symptoms and signs of HE and is documented by neuro-psychometric (NP) tests and neurophysiological tests, but, HE grade 1 is defined by the presence of mild clinical alterations like euphoria, anxiety or a shortened attention span. Although the consequences are serious, mostly CHE is often unnoticed or even neglected in routine clinical practice due to only very mild symptoms associated with grade 1, or not performed diagnostics in case of MHE 30, 31 .
Cirrhotic Cardiomyopathy
The cirrhotic cardiomyopathy was present in about 50% In patients with advanced cirrhosis. It is defined as a chronic cardiac dysfunction characterized by impaired contractile response and/or altered diastolic relaxation in the absence of other cardiac causes. The pathophysiology of this condition is apparently related to PH and hyperdynamic state in cirrhosis 32 . In cirrhotic patients many factors contribute to systolic and diastolic dysfunction. These factors included plasma volume expansion leading to a relative central volume decrease 33 , decreasing the arterial vessel wall thickness and tone leading to reduced arterial compliance 34, 35 and also, autonomic dysfunction 36 . Symptoms associated with cirrhotic cardiomyopathy include dyspnea with exertion, impaired exercise capacity, paroxysmal nocturnal dyspnea, peripheral edema, and orthopnea. Lessfrequent presentations include long QT on electrocardiography, arrhythmia, and sudden death 37 .
Diagnosis of Portal Hypertemsion
The range of HVPG measurements can provide clinically useful information in terms of the prognosis related to portal hypertension and its complications, fig. ( 3) 38 . 
Indirect Portal Pressure Measurement
Measurement of HVPG remains the gold standard method to assess portal pressure (PP) through catheterization of the hepatic vein using a balloon catheter 39 . Normal values of HVPG lies between 3 and 5mm Hg. Patients with HVPG values above 5 mmHg but less than 10 mm Hg are defined to have mild PH while those with values above 10 mmHg are defined to have clinically significant portal hypertension (CSPH). Patients have CSPH with HVPG >12 mm Hg are at increased risk of variceal bleeding. Reduction of the HVPG to levels of 12 mm Hg or below is found to have protective effect in terms of variceal hemorrhage (VH) 40 .
Noninvasive Imaging Diagnosis
Ultrasound is the first-line imaging examination to be performed in patients with suspected cirrhosis and/or portal hypertension. Ultrasound is safe, can be repeated easily, is not expensive and is highly sensitive in detecting thrombosis in the portal vein and hepatic veins, so allowing a correct differential diagnosis of new cases of portal hypertension 41 . As for the limitations, inter-observer variability is considered a major drawback, but appropriate training and knowledge markedly reduce it. Intestinal gas and obesity limit the exploration. Presence of portosystemic collaterals provides the most reliable clue to diagnose portal hypertension 42 . Measuring liver stiffness using magnetic resonance elastography (MRE) can predict severe PHT in asymptomatic or compensated cirrhosis 43-45 . Evaluation of hepatic and splenic stiffness provides noninvasive modality for screening for PHT. Normal values of hepatic stiffness lies below 2.9 kPa. CSPH can be diagnosed with values >20-25 kPa, with a diagnostic accuracy over 90% 35, 36 . However, limitations of MRE include its high cost and limited availability, which currently prevent its use as a routine diagnostic method. So that, it is currently possible to diagnose liver cirrhosis and portal hypertension accurately by non-invasive methods in a reasonable proportion of patients with chronic liver disease. However, all methods have pros and cons. New, more sophisticated non-invasive diagnostic methods such as MRE, new software analysis of images obtained with the existing technology such as the analysis of the nodularity of liver surface on ultrasound and CT images and dynamic techniques on MRI are emerging tools further improving this possibility.
